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Abstract
Background: The use of gene signatures can potentially be of considerable value in the field of clinical diagnosis.
However, gene signatures defined with different methods can be quite various even when applied the same disease
and the same endpoint. Previous studies have shown that the correct selection of subsets of genes from microarray
data is key for the accurate classification of disease phenotypes, and a number of methods have been proposed for the
purpose. However, these methods refine the subsets by only considering each single feature, and they do not confirm
the association between the genes identified in each gene signature and the phenotype of the disease. We proposed
an innovative new method termed Minimize Feature’s Size (MFS) based on multiple level similarity analyses and
association between the genes and disease for breast cancer endpoints by comparing classifier models generated from
the second phase of MicroArray Quality Control (MAQC-II), trying to develop effective meta-analysis strategies to
transform the MAQC-II signatures into a robust and reliable set of biomarker for clinical applications.
Results: We analyzed the similarity of the multiple gene signatures in an endpoint and between the two
endpoints of breast cancer at probe and gene levels, the results indicate that disease-related genes can be
preferably selected as the components of gene signature, and that the gene signatures for the two endpoints
could be interchangeable. The minimized signatures were built at probe level by using MFS for each endpoint. By
applying the approach, we generated a much smaller set of gene signature with the similar predictive power
compared with those gene signatures from MAQC-II.
Conclusions: Our results indicate that gene signatures of both large and small sizes could perform equally well in
clinical applications. Besides, consistency and biological significances can be detected among different gene
signatures, reflecting the studying endpoints. New classifiers built with MFS exhibit improved performance with
both internal and external validation, suggesting that MFS method generally reduces redundancies for features
within gene signatures and improves the performance of the model. Consequently, our strategy will be beneficial
for the microarray-based clinical applications.
Background
A condition’s gene signature is defined as the group of
genes in a given cell type whose combined expression
pattern is uniquely characteristic of that condition [1].
The use of gene signatures can potentially be of
considerable value in the field of clinical diagnosis.
However, gene signatures defined by different investiga-
tors using different methods can be quite various even
when applied on the same disease and the same end-
point. Therefore, it brings noise to the microarray-based
clinical applications. For example, in the second phase
of the MicroArray Quality Control (MAQC-II) project
[2], a total of 19 780 gene signatures were defined by
over 30 data analysis teams (DATs) for 13 endpoints.
Interestingly, the genes identified in each gene signature
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natures failing to share any gene in common. However,
despite the variability of these gene signatures, they still
have relatively good predictable power. Then an impor-
tant question is raised that why so many gene signatures
can be selected for the same disease with similar predic-
tive performance. Whether there is any signature that
contains the smallest number of genes and has good
performance at the same time?
Previous studies have shown that the correct selection
of subsets of genes from microarray data is key for the
accurate classification of disease phenotypes [3], as this
procedure not only removes features that do not provide
significant incremental information, but also enables
more rapid and efficient analysis [4]. To this end, a
number of studies have been proposed [3,5-9]. One of
them is the so-called minimum redundancy-maximum
relevance (MRMR). This method employs features that
are maximally dissimilar to each other in terms of Eucli-
dean distances or pair-wise correlations [3]. Based on
MRMR method, Incremental Feature Selection (IFS) has
been employed to determine how many features in the
list MRMR generated should be selected [5]. An alterna-
tive strategy, called joint core genes, makes use of two
independent lung cancer microarray datasets [6] to
increase robustness of prediction. Sparse linear pro-
gramming (SPLP) [10] represents a third approach
which has been applied to a large microarray dataset
derived analyzing from liver gene expression of com-
pound-treated rats. In this third approach, a necessary
gene set (NGS) is constructed through a stripping pro-
cedure, after which no valid signature can be derived
from its complement (i.e. all genes present on the array
minus the NGS) [7]. Support Vector Machine methods
based on Recursive Feature Elimination (SVMRFE)
refine the optimum feature set by using SVM-train to
compute the ranking criteria, which eliminate the fea-
ture with smallest ranking criterion [8,9]. Like SVMRFE,
recursive feature addition (RFA) employs supervised
learning, and combines it with statistical similarity mea-
sures [9]. However, these methods refine the subsets by
only considering each single feature. Furthermore, none
of them have confirmed the fundamental association
between the genes identified in each gene signature and
the phenotype of the disease, which is considered to be
important in clinical applications.
MAQC-II is a collaborative research project that
includes individuals from multiple data analysis teams
(DATs) to generate gene expression signatures for three
clinical datasets and three toxicogenomics datasets [2],
and offers a valuable chance for studying the relation-
ship between gene signatures and their genes. Each
DAT has the freedom to choose their own method for
signature development, which has lead to many different
signatures with similar predictive power for the same
endpoint. The diversity of the gene signatures being lar-
gely attributed to the different modeling processes
[11-13] that has been applied to the data. Consequently,
these MAQC-II gene expression signatures offer a
unique opportunity to develop novel meta-analysis stra-
tegies that yield a minimum set of features with maxi-
mum predictive power.
In this study we have sought to develop effective
meta-analysis strategies to transform the MAQC-II sig-
natures into a robust and reliable set of biomarker for
clinical applications.
The analyses workflow is outlined in Figure 1. Specifi-
cally, we first conducted signature similarity analyses at
probe level, which can select probes that are consistently
considered by multiple signatures, results in a subset of
features (probes) that were further analyzed using a
method designated Minimize Feature’sS i z e( M F S ) .M F S
is an iterative backward stepwise elimination method
with the purpose of minimizing the gene set (i.e.,
removing uninformative genes while retaining these
essential to the endpoint studied) and thus generating a
signature of smaller size and improving predictive
power based on the resultant feature set. On the other
hand, analyses at gene level and gene ontology (GO)
level were proposed to confirm biological significance.
The analyses are focused on two endpoints of the
MAQC-II breast cancer datasets, i.e., pathologic com-
plete response (denoted as endpoint D hereafter) and
estrogen receptor status (denoted as endpoint E here-
after). The datasets contain a training dataset and a vali-
dation dataset [14]. The minimized signatures were built
on the training dataset and be validated on the valida-
tion dataset. Correspondingly, the swap models are sig-
natures built on validation dataset and be validated on
the training dataset. It is worthwhile to mention that the
training and validation datasets are profiled separately in
different timeframes, thus providing a real-world clinical
application scenario.
Results
Similarity analyses at probe level
Thirty-two gene signatures for endpoint D and 22 for
endpoint E were used for the similarity analyses. Over-
lap matrices at probe level for each of two signatures
were constructed (Additional file 1 and 2). For endpoint
D, 345 probes appeared at least twice among a total set
of 1 747 (19.75%), whereas for endpoint E, 644 probes
appeared among 1 760 (36.59%) (Table 1). The gene
ESR1 or estrogen receptor 1 (Probe 205225_at) appears
21 and 19 times in endpoints D and E, respectively,
ranking top 1 in both groups (Additional file 3). How-
ever, the comparison among all the involved models for
each endpoint revealed that not all DATs chose the
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selection criteria were not consistent (Additional file 4).
Further analyses about probesets for both endpoints are
available in Additional File 5.
Model development based on the optimal set of features
and the validation
The minimized signatures were built by MFS based on
the result of similarity analysis at probe level. The para-
meters and performances of our new models,
BR_D_Model and BR_E_Model, are listed in Table 2.
For each endpoint, Matthew’s correlation coefficient
(MCC) of internal validation was improved using the
MFS method, and values of validation dataset also per-
formed well. The intervals of external validation values
for all input classifiers were [-0.2482, 0.3863] (mean =
0.2702, variance = 0.0213) for endpoints D and [0.499,
0.792] (mean = 0.7105, variance = 0.0062) for endpoint
E, respectively; the maximum value in both endpoints
was slightly smaller than those of BR_D_Model (0.395)
and BR_E_Model (0.819). Further external validations
on endpoint E with EV1 dataset [15-17] and EV2 dataset
Figure 1 Analysis workflow. This figure illuminates the general outline of the whole process.
Table 1 Overlap at the levels of probes and genes
Probe Gene
Models Endpoint Model
Number
Mean (Variance) Total Overlapped Rate
(%)
Endpoint
Overlap
Total Overlapped Rate
(%)
Endpoint
Overlap
Normal D 28 97.04 (91310.26) 1747 345 19.75 785 1350 402 29.78 619
E 22 143.5 (95148.74) 1760 644 36.59 1309 589 45.00
Swap D 20 54.10 (3964.62) 609 207 33.99 317 465 174 37.42 252
E 20 106.05 (32074.79) 1047 443 42.31 793 416 52.46
This table shows prime analyses at levels of probes and genes for normal models and swap models. Total refers to the total number of irredundant probes and
genes, with means and variances of models for each endpoint be listed in Mean (Variance). Rate refers to the proportion of overlaps in unique sets of probes and
genes. The numbers of overlaps between unique sets of probes and genes of both endpoints are calculated, which are displaced in Endpoint Overlap. Note that
two probes for NIEHS_BR_E_5 were removed as they do not appear in the Affymetrix U133A platform. We compared lists of probes for each group of data to
get overlaps at probe level. If two probes overlapped at probe level, they must also overlap at gene level; if two probes are not same but they share the same
gene, they can also overlapped at gene level. This table suggested that the overlap rates of endpoint E are always greater than those of endpoint D. For normal
models, the number of features for both endpoints have no significant difference (F = 0.9507, T-test = 0.5748) and there is either no significant difference for
that of swap models (F = 0.1236, T-test = 1.2238, degree of freedom = 23.6263). Furthermore, overlap rates at gene level are greater than those at probe level,
suggested that the number of non-identical probes which share the same genes is large.
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predictions (reverse) were also carried out between vali-
dation dataset and training dataset based on swap mod-
els submitted by DATs. However, the results of two
new models from swap validations (Swap_BR_D_Model
and Swap_BR_E_Model) were not as good as the inde-
pendent validations of the best model (Table 2).
To systematically evaluate the performances of these
original models and swap models, heatmaps for these
signatures on training dataset and validation dataset
were created (Figure 2 andAdditional file 7). Further-
more, a three-dimensional graph was plotted, based on
values of their MCC, Val_MCC (Validation MCC) and
Std_Dev (standard deviation). A model that is located at
upper left corner in this graph tends to have better
MMC and Val_MCC with small standard deviation, and
better performance. Our models for two endpoints are
located at upper left corner and on the top of all other
models displayed in the graphs (For BR_D_Model, MCC
= 0.707, Val_MCC = 0.395, Std_Dev = 0.030; For
BR_E_Model, MCC = 0.904, Val_MCC = 0.819, Std_Dev
= 0.029) (Table 2 and Figure 3).
Biological significance among signatures
To identify the biological significance among signatures,
we first performed the similarity analyses at gene level
and GO level. The number of genes shared by different
signatures for each endpoint was quite large, and a gene
can be selected more than once by a signature since
multiple probes on the microarray can map to a single
gene. For endpoints D and E, 29.8% and 45.0% of the
total genes appeared in common, among which CA12
(carbonic anhydrase XII) related probes appeared 67
and 61 times, respectively (Table 3 and additional file
8). Then we carried out GO enrichment analysis using
the GoMiner algorithm [19], and GO terms were sorted
according to the number of genes associated within the
5th level (Additional file 9). The enrichment results of
biological process for both endpoints are regulation of
cellular metabolic process, and those of cellular compo-
nent for both are intracellular part. The results of mole-
cular function are sequence specific DNA binding and
actin binding for endpoints D and E, respectively.
To further validate the biological significance, we ana-
lyzed the similarity between two endpoints at probe and
Table 2 Model parameters and performances
UniqueModelID BR_D_Model Swap_BR_D_Model BR_E_Model SwapBR_E_Model
Endpoint D D E E
Dataset training dataset validation dataset training dataset validation dataset
Samples 130 100 130 100
Features 32 33 55 10
Normalization MAS5 MAS5 MAS5 MAS5
Batch Effect Removal Method AGC AGC none None
Feature Selection Method MCC-robustness MCC-robustness MCC-robustness MCC-robustness
Classification Method SVM SVM SVM SVM
Internal Validation 5F-CV 5F-CV 5F-CV 5F-CV
Validation Iterations 10 10 10 10
MFS Fitting Index index1 index1 MCC MCC
MFS Optimized Method SVM SVM SVM SVM
MFS Best Fitting Model yes yes yes yes
CV_MCC 0.707 0.689 0.904 0.942
CV_ACC 0.892 0.827 0.955 0.972
CV_SEN 0.915 0.673 0.947 0.955
CV_SPE 0.815 0.981 0.959 0.983
MCC_Std Dev 0.030 0.082 0.029 0.021
ACC_Std Dev 0.011 0.048 0.014 0.010
SEN_Std Dev 0.011 0.091 0.017 0.024
SPE_Std Dev 0.026 0.013 0.013 0.000
Val_MCC 0.395 0.368 0.819 0.661
Val_ACC 0.850 0.792 0.910 0.838
Val_SEN 0.907 0.714 0.841 0.914
Val_SPE 0.500 0.802 0.964 0.811
ACC is short for Accuracy, SEN for Sensitivity, SPE for specificity and StdDev for standard deviation. The CV rows refer to internal validation and the Val rows refer
to validation of the training dataset against the validation dataset. We balanced the training dataset for Swap_BR_D_Model, as the P/N ratio is too small (0.18), as
MCC is very sensitive and its value might change a lot even for a small predictive error in P/N ratio (positive/negative ratio) unbalanced datasets. Features of
BR_D_Model and BR_E_Model are available at Additional file 17.
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were common to both endpoints; 16.90% of probes
(131) were unique for endpoint D, while 55.48% (430)
were unique for endpoint E. Comparisons at the gene
level gave similar results. About 31% of genes (236)
were common to both groups, while 21.99% (166) and
46.75% (353) of genes were unique to endpoints D and
E, respectively. Interestingly, these two endpoints for
breast cancer share a large number of overlapping
probes and genes.
Noticeably, the observation that the two endpoints for
the same disease share a lot of genes raised the possibi-
lity that the gene signatures for both endpoints could be
interchangeable. We tested this hypothesis by cross-pre-
diction with two minimized signatures, i.e. signatures
for endpoint D were used for prediction tasks of end-
point E and vice versa. Interestingly, subsequent analysis
results confirmed our hypothesis, although these two
endpoints represent two different aspects of breast can-
cer. With the model BR_D_Model to predict the end-
point E, we obtained a MCC of 0.839 for internal
validation, and 0.719, 0.715 and 0.727 for validation
datasets, EV1 dataset and EV2 dataset, respectively.
With BR_E_Model to endpoint D, the internal validation
result is 0.142, and validation result for validation data-
set is 0.349. Moreover, clinical data show that associa-
tions between these two endpoints were significant [20],
and this association was confirmed by Kendall’sr a n k
correlation test (z = -5.9038, P = 3.551 × 10
-9)w i t h
MAQC-II breast cancer datasets.
Furthermore, protein-protein interaction (PPI) topol-
ogy property changed marginally between probes of the
minimized signatures and their input, which is also a
support to biological significance. All-pairs shortest path
matrices [21] were constructed for each pair of probes
in the minimized gene signatures based on a unique PPI
network data archived at UniHI for Affymetrix probes
[22]. That is, from the node of the first probe in a pair,
we searched for the second one in the network using
the Breadth First Search (BFS) algorithm [21]. For each
pair within the matrix, three outcomes were potential:
(1) one or both of them are not in the network, (2)
there is no link between the pairs, and (3) the pair is
linked. We defined the average length of the matrix as
the mean of all linked pairs, and k-th level neighbor as
the pair of probes whose distance between them is k. It
suggested that the number of third and fourth level
neighbors, and pairs that are not connected decreased
sharply. However, that the average lengths of shortest
path matrices changed marginally, and that all 6 levels
(from first to sixth) remain between probes of the mini-
mized signatures and their input, suggesting that the
topological properties of the PPI subsets consist of
stable features, which are not changed by MFS (Addi-
tional file 10).
Discussion
Gene signatures of large and small size could perform
equally well in clinical applications. For example, the
NIEHS and SAI predictors for the breast cancer
Figure 2 Heatmaps for gene signatures on validation dataset. (a) Heatmap for BR_D_Model; (b) Heatmap for BR_E_Model. Each column
represents a sample in the dataset, and each row represents a gene in the gene signature. Note that the end row is endpoint status.
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BR_E_1 [51 features] respectively) have close predictive
powers (Validation MCC of both signatures is 0.748),
but completely different feature sizes. The above sug-
gests that it is probable to minimize the size of gene sig-
natures while maintaining their predictive power. This
notion is also supported by previous study that small
gene signatures can perform well in discriminative ana-
lyses [23].
Biological importance can be inferred through simple
similarity analyses of gene signatures for each studied
endpoint on the overlapping genes. Interestingly, a num-
ber of predictive gene markers were experimentally con-
firmed to be related to breast cancer (Table 3). These
observations are consistent with all other predictable
endpoints of the MAQC-II project. For example, CA12,
a highly correlated gene with estrogen receptor a (ERa),
is robustly regulated by estrogen via ERa in breast
cancer cells, and this regulation involves a distal estro-
gen-responsive enhancer region [24,25]. ESR1 encodes
an estrogen receptor, a ligand-activated transcription
factor composed of several domains important for hor-
mone binding, DNA binding, and activation of tran-
scription [25]. Besides, high levels of MAPT
(microtubule-associated protein tau) mRNA expression
in ER-positive breast cancer indicate an endocrine-sensi-
tive, but chemotherapy-resistant disease. In contrast, low
tau expression levels are associated with a subset of ER-
positive cancers that have poor prognosis with tamoxi-
fen alone and may benefit from taxane-containing che-
motherapy [26]. Moreover, GATA3 (GATA binding
protein 3) is reported as a breast cancer marker and is
expressed almost among all ER-positive tumors [25].
Low levels of GATA3 are associated with invasive breast
carcinomas [25]. Numerous studies, notably based on
microarray data, have shown that expression of GATA3
Figure 3 Performances of original and swap models based on classification algorithm level similarity analysis. a) Endpoint D original
models; b) Endpoint E original models; c) Endpoint D swap models; and d) Endpoint E swap models. Coordinate axes are MCC (internal
validation), Val_MCC (external validation) and MCC_Std (internal validation standard deviation). Each classification algorithm is represented by a
different color. The radius of each sphere is related to the number of model features, within a range of 50-1 000. The blue stars are our own
models, while spheres are models from which our models were developed.
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The strong correlation between ESR1 and GATA3
expression in breast cancer tissues implies that GATA3
might cooperate with this steroid receptor to regulate
breast tissue-specific hormone-responsive genes [27].
Since the minimization process can remove probes
regardless of their ranking, some top-ranked probes are
removed without affecting the predictive power of the
model. To find out the reasons, we re-mapped the
probes for two minimized signatures to corresponding
genes, and no overlapping gene was found in the re-
mapped list for BR_D_Model and only 4 genes over-
lapped in BR_E_Model. That is, probes with more than
one corresponding genes were rarely observed after the
minimized process. To further inquire this phenomenon,
we also examined the distribution of these genes based
on the pathways archived at MsigDB [28]. Although the
number of genes in the signatures was small, a large
number of pathways were found to be represented, and
most of these pathways included only one or two genes
in each pathway. Among the genes involved in multiple
pathways, CCND1, IL8, IGF1R,a n dMYB participate in
more than 40, while numerous genes involve in same
pathways, e.g. BRCA_ER_NEG, BRCA_ER_POS, STEM-
CELL_NEURAL_UP,a n dLEI_MYB_REGULAT-
ED_GENES. This finding suggests that our minimized
gene signatures are highly representative of multiple
important pathways that may be involved in the biologi-
cal processes underlying the discrimination of normal
tissue from breast cancer samples. In that way, the ratio-
nale behind the phenomenon could be as follows: when
some top-ranked overlapping probes are removed, the
non-overlapping probes retain sufficient discriminatory
power as the remaining probes could still stands for the
majority of genes and pathways.
Based on the essence of feasibility for the minimized
methodology and biological functions inferred under
similarity analyses, we further explored the rationale for
the consistency and the diversity of the gene signatures.
The gene signatures generated from different teams for
the same clinical outcome are different from each other,
with some failing to share any gene in common. The
diversity could result from the use of different feature
selection methods, classification algorithms etc. Simi-
larly, gene signatures for different clinical outcomes of
same disease have been shown to exhibit little overlap
between features [29-31], This observation has been
attributed to the use of multiple factors, such as differ-
ent datasets, feature selection methods, classification
algorithms sample sizes, and patient diversity [32,33].
The diversity of patients includes environmental effects,
age and sex, disease stages, and patient health. In addi-
tion, genes involved at different disease stages or with
different disease subtypes could also be different.
Furthermore, the assumptions (i.e. gene independence)
for the statistical models used in gene marker identifica-
tion do not typically hold up given the small sample
sizes and complexity of gene interactions.
Despite of these complex issues, in some rare cases
the predictive power of each model has been indepen-
dently validated with large numbers of patients, and all
have shown similar performance [32].
Table 3 Biological associations between genes and breast cancer
Gene General description Support Endpoint D Endpoint E
Overlap Position Overlap Position
CA12 Highly correlated with Era +6 7- 56 14
MAPT prognostic values in ER(+) Primary breast cancers in 3 patient cohorts + 43 -7 22 26
ESR1 Involved in pathological processes of breast cancer + 33 -2 53 1
GATA3 A breast cancer marker + 25 -14 40 6
BTG3 Protein coding 22 75 -142
NFIB Differentially expressed reported [39] 22 84 20 -61
LDHB Protein coding 21 27 -239
RARRES1 Downregulated reported [40] 20 2 19 -2
CCND1 Aberrantly regulated and could contribute to therapeutic failure in the context of ER-
positive breast cancer
+ 18 -56 145
ELF5 Downregulated reported [41] 16 7 -16
IL6ST Protein coding -60 33 60
SLC39A6 Coregulated with estrogen receptor in some breast cancers + -64 25 41
TBC1D9 Protein coding -25 25 19
ABAT Protein coding -34 16 29
Genes marked ‘+’ indicates experimental support for a role in breast cancer in Support. Unless otherwise stated, descriptions were collected from Entrez Gene
[25]. Numbers in the Overlap reflect number of gene overlap, for the top 10 ranked genes of two endpoints. Values for Position reflect these genes’ rank in the
descending sorted list of fold-change values, signs of which represent gene positions in the two ends of the list. Almost all top 10 genes for each endpoint rank
in the top 200 up-regulated or down-regulated genes. Furthermore, among the genes common to these two endpoints, the change in expression level was not
always correlated. In other words, genes up-regulated in endpoint D could be down-regulated in endpoint E.
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probe redundancy reduction with the MFS process. Sev-
eral factors may contribute to this significance. First, the
input for MFS are not all overlapping probes but probes
with a sticker criterion which can minimize the random
effect and improve the predictive power of signature,
the reason behind this is that different DATs have dif-
ferent modeling factors, which contain randomicity and
are evaluated by MAQC-II [2]. Besides, during the fea-
ture selection process, numerous different statistical
strategies have been applied for this purpose, but those
features in a gene signature were purely selected based
on statistical significances, some of them may not have
any relation to the studied endpoint phenotype but
somehow are correlated to the genes related to the end-
p o i n t .T h o s ef e a t u r e sm a yn o th a v et h ep o s i t i v ec o n t r i -
bution to the model performance but generate certain
noise to interfere with the predictive ability. Our
method can identify those genes and exclude them from
the minimized features, eventually, lead to improve the
predictive power.
MFS method generally reduces redundancies for fea-
tures within gene signatures and improves the perfor-
mance of the model (Table 2), which indicates the
existence of consistency for the studying endpoint. Clinical
applications will benefit from the gene signature reduction,
since the reduced size of gene signature with similar or
better performance can increase the efficiency and reduce
cost. Meanwhile, most of the features remaining in the
minimized gene signature tend to have a strong associa-
tion with the disease and the application of those disease
oriented features in diagnosis is more informative. To
s o l v et h i sp r o b l e m ,w eu s ean MCC-robustness value
(Methods) as a measurement for feature selection process
and examine their biological functions through GO term
analysis. However, the predictive power of newly-gener-
ated classifiers depends on the quality of training and vali-
dation datasets, as well as the collected features and the
selected classification algorithm. A newly generated gene
signature by MFS would never perform well if the perfor-
mance of its input signatures is not good.
MFS could benefit the clinical applications of microar-
ray technology in several ways. Firstly, it could improve
the predictive power of signatures, which is a probable
contribution to the implementation of personalized
medicine; secondly, it minifies the number of probes in
signatures, which can reduce cost for microarray’s appli-
cations, and more important, it can avoid the weak-
nesses of large-size signatures: the insufficiency of
sample, relevance among features, and the possible inac-
curacy. Thirdly, the similarity analyses can disclose the
consistency and diversity among signatures for a disease,
which is related to the essential of the disease.
Conclusion
Generally, our analyses of results from MAQC-II project
indicate that gene signatures of both large and small
sizes could perform equally well in clinical applications.
In that way, it is reasonable to minimize the size of gene
signatures. Besides, biological significances can be
inferred through similarity analyses, the results of which
are the expected consistency for multiple gene signa-
tures, reflecting the studying endpoints. MFS was devel-
oped following this principle. As a result, new classifiers
built with minimized features based on similarity ana-
lyses can reflect breast cancer-related pathways, and can
always have a smaller size and a significant predictive
power. No doubt, the strategy could help the microar-
ray-based clinical applications.
Methods
Datasets and endpoints
Totally we analyzed two binary endpoints: pathologic
complete response (endpoint D) and estrogen receptor
status (endpoint E). MAQC-II provided two key data-
sets: training dataset [14] and validation dataset [14].
Training dataset contains 130 samples (33 positives and
97 negatives for endpoint D, 80 positives and 50 nega-
tives for endpoint E), and validation dataset contains
100 samples (15 positives and 85 negatives for endpoint
D, 61 positives and 39 negatives for endpoint E). EV1
dataset [15-17] and EV2 dataset [18] were also used for
external validations. All datasets were generated using
Affymetrix U133A or U133B platforms, with their
research targets be endpoint D or endpoint E. More
parameters for datasets are available at Additional file
11.
For new gene signatures, we utilize the classification
method of support vector machine (SVM) and repeat
five-fold cross validation (5F-CV) ten times, using the
training dataset as an internal reference. The minimized
signatures were built on the training dataset and vali-
dated on the validation dataset, and extra-validations for
endpoint E were also proposed using EV1 dataset and
EV2 dataset. Correspondingly, the swap models are sig-
natures built on validation dataset and be validated on
the training dataset. It is worthwhile to mention that the
training and validation datasets are profiled separately in
different timeframes, thus providing a real-world clinical
application scenario.
Preprocessing for the input models
Preprocessing was used as a quality control process.
Some of the models were selected for our research,
from 2 997 models for endpoint D and 1 196 for end-
point E models, among which informal models were
excluded. However, only features of about 30 gene
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Page 8 of 11signatures for each endpoint are available. A null check
for key attributes was also proposed, that is, an item
would be discarded if any of its key attributes are
absent. Models’ parameters are provided as Additional
file 12 and 13.
Similarity analyses
For each endpoint, similarity analyses were performed,
at the level of probe, gene and GO. Probes extracted
from different signatures were compared to identify
overlap at the probe level, and a unique set of probes
was generated, which only contains these probes identi-
fied by at least two sources (or a sticker criterion). At
the gene level, the unique set of genes was generated in
a similar way. Yet, transforming probes to correspond-
ing genes presents a challenge, as some probes have
more than one corresponding gene on the Affymetrix
platform. For probes that only have one corresponding
gene, an Affymertix annotation file for U133A platform
is used [34]. If genes that correspond to a given probe
are isoenzymes or aliases, then they should be consid-
ered as one, while pseudogenes and hypothetical genes
were excluded. For the remaining probes, we trans-
formed them to its closest gene using a Bayesian-Deci-
sion Tree (Bayesian-Decision Tree document in
Additional file 14.
At the GO level, GoMiner [19], a freely available gra-
phical user interface program developed by Zeeberg et
al (2003), was used to calculate the relative enrichment
factor and the most involved pathways for the gene sig-
natures. The entire gene list for Affymetrix U133A was
defined as total genes for each endpoint, while genes
extracted from input gene signatures were defined as
subsets. GO Categories terms with p-values larger than
0.05 were excluded. The categories lists were sorted by
number of genes with changing expression, and top
terms of biological process, cellular component, and
molecular function were selected out, respectively.
There are two supplemental similarity analyses along
with the previous mentioned levels. Analysis of gene
expression level is available at Local Network Model
(LNM) document in Additional file 15. The classifica-
tion algorithm level similarity analysis was based on ana-
lysis of three-dimensional graphs of model performances
for original models and swap models (Figure 3).
Similarity analyses between endpoints D and E were
also carried out at multiple levels. At the levels of probe
and gene, we checked the percentage of unique probes
and genes and overlapping probes and genes shared by
both endpoints and the particular shares for each end-
point. Besides, mean equal test for both endpoints were
proposed for normal models and swap models (Table 1).
At GO level, top-ranked terms for the two endpoints
were compared for all three GO categories to see if
there is any term shared by both endpoints. To further
process the similarity analyses between both endpoints,
we proposed cross-prediction between these two
endpoints.
Generating a new gene signature by MFS
A Java console program called Minimize Feature’sS i z e
(MFS) was implemented based on WEKA’s application
program interface [35]. It took three inputs, (1) an
ARFF file (the default file format of WEKA), from
which we obtained the feature list, expression profile
data and the endpoint status, (2) a criteria value for
MCC, and (3) the classifier’s name. Three major goals
were devised for MFS: minimal feature size, maximal
internal MCC value, and maximal external MCC value.
We merged features of the input gene signatures to a
unique weighted set. For each gene signature, we
assigned the probes’ weight with MCC-robustness values,
as an un-weighted method do not considers the quality
of probes, on a hypothesis that qualities of probes of a
well-performed gene signature are better than those of
bad-performed ones. MFS can accept multiple inputs,
from multiple gene signatures to the probes of a single
gene signature or probes obtained by using LNM (details
are available at MFS document in Additional file 16.
During the analyses, we constructed the gene signa-
ture, eliminating genes that do not provide substantial
additional information [4], or that are redundant based
on similarity analyses. Fundamentally, MFS is a back-
ward stepwise elimination [36]: For each iteration, we
calculated the starting MCC value of the gene signature;
Next, for each feature in the given gene signature, MFS
calculated a new MCC value without the feature. If the
new MCC value was less than the old one, MFS
restored the previous conditions and omitted this probe;
otherwise, it moved to the next probe. At the end of
each iteration, MFS checked the MCC value. If it was
greater than the given criteria value, MFS produced an
intermediate result and then went on to the next itera-
tion. If the size of the gene signature no longer
decreased after an iteration or if the size was less or
equal than a given criterion (default 5), MFS terminated
the process and recorded the model marked as ‘best’.
Note that the ‘best’ model was saved whether its MCC
value was larger than the given cutoff or not. It is also
possible to use other indices to do the fitting process
(see Statistical analysis).
Array-generation based gene centering (AGC) of the
d a t a s e t sw a su s e da sa no p t i o n a lp r o c e s si nM F St o
remove background noise [37]. External validation of
newly produced ARFF files would be executed to check
the stability of the new gene signatures. Only gene sig-
natures that performed well both in internal and exter-
nal validations were retained.
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We used the MCC [38] as the index for classifier pre-
dictive power. TP = true positive, TN = true negative,
FP = false positive, FN = false negative.
MCC =
TP × TN − FP × FN

(TP + FP)(TP + FN)(TN + FP) (TN + FN)
An MCC-robustness value is used to measure the pre-
dictive power and its stability of a classifier, a measure-
ment index for top probes’ s e l e c t i o ni nt h eM F S .A
well-performed classifier would have a larger MCC
value and a smaller standard deviation. Once the MCC-
robustness value approaches infinity it is assigned the
smallest weight.
MCC − robustness =
MCC
σMCC
Other indices that were used in the MFS fitting pro-
cess besides MCC:
index1 =
TP × TN
(TP + FP)(TN + FP)
index2 =
TN
TN +F P
+
TP
TP + FP
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